MEP56408A - Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane - Google Patents

Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane

Info

Publication number
MEP56408A
MEP56408A MEP-564/08A MEP56408A MEP56408A ME P56408 A MEP56408 A ME P56408A ME P56408 A MEP56408 A ME P56408A ME P56408 A MEP56408 A ME P56408A
Authority
ME
Montenegro
Prior art keywords
conjugates
production
biological membranes
methods
molecules via
Prior art date
Application number
MEP-564/08A
Other languages
English (en)
Inventor
Eugen Uhlmann
Beate Greiner
Eberhard Unger
Gislinde Gothe
Marc Schwerdel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP56408A publication Critical patent/MEP56408A/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)

Abstract

Predmet ovog pronalaska su konjugati, postupci za njihovu proizvodnju i primarna tih konjugata za transport niskomolekularnih jedinjenja i makromolekula kroz biološke membrane, posebno za transport molekula u ćelije. Predmet ovog pronalaska su i ljekovi i sredstva dijagnostike, kao i testkompleti, u kojima se ovi konjugati nalaze, odn. primjenjuju.
MEP-564/08A 1999-07-28 2000-07-20 Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane MEP56408A (bs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19935302A DE19935302A1 (de) 1999-07-28 1999-07-28 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
PCT/EP2000/006936 WO2001008707A2 (de) 1999-07-28 2000-07-20 Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen
YUP-903/01A RS51447B (sr) 1999-07-28 2000-07-20 Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane

Publications (1)

Publication Number Publication Date
MEP56408A true MEP56408A (bs) 2011-05-10

Family

ID=7916258

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-564/08A MEP56408A (bs) 1999-07-28 2000-07-20 Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane

Country Status (33)

Country Link
US (1) US8420396B2 (bs)
EP (1) EP1204430B1 (bs)
JP (1) JP4791665B2 (bs)
KR (1) KR100721696B1 (bs)
CN (1) CN1227035C (bs)
AR (1) AR029385A1 (bs)
AT (1) ATE447413T1 (bs)
AU (1) AU776114B2 (bs)
BR (1) BR0012757A (bs)
CA (1) CA2377977C (bs)
CY (1) CY1109744T1 (bs)
CZ (1) CZ2002300A3 (bs)
DE (2) DE19935302A1 (bs)
DK (1) DK1204430T3 (bs)
EE (1) EE05303B1 (bs)
ES (1) ES2335741T3 (bs)
HK (1) HK1047042A1 (bs)
HR (1) HRP20020074B1 (bs)
HU (1) HUP0201995A3 (bs)
IL (2) IL147527A0 (bs)
ME (1) MEP56408A (bs)
MX (1) MXPA01013114A (bs)
NO (1) NO334155B1 (bs)
NZ (1) NZ516838A (bs)
PL (1) PL202881B1 (bs)
PT (1) PT1204430E (bs)
RS (2) RS20100249A (bs)
RU (1) RU2275936C2 (bs)
SI (1) SI1204430T1 (bs)
SK (1) SK287654B6 (bs)
TR (4) TR201109491T2 (bs)
WO (1) WO2001008707A2 (bs)
ZA (1) ZA200200657B (bs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
WO2005024033A2 (en) * 2003-09-11 2005-03-17 Universitätsklinikum Schleswig-Holstein Campus Lübeck Nucleotide sequences promoting the trans-membrane transport of nucleic acids
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
EP1645288A1 (en) * 2004-10-07 2006-04-12 CTG Pharma S.r.l. New nuclear transcription factors regulators
KR100690199B1 (ko) * 2006-04-20 2007-03-12 이화여자대학교 산학협력단 구리 이온 선택성을 갖는 플루오레세인 유도체, 이의제조방법 및 이를 이용한 생체 내 구리 이온 검출방법
RU2010112771A (ru) * 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
BR122020024394B1 (pt) * 2010-12-29 2021-05-11 F. Hoffmann-La Roche Ag conjugado e composição farmacêutica
TWI726844B (zh) * 2014-05-23 2021-05-11 美商健臻公司 胜肽載體上之多重寡核苷酸部分
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
WO2018026965A1 (en) 2016-08-02 2018-02-08 Isi Life Sciences, Inc. Compositions and methods for detecting cancer cells in a tissue sample
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
US10539567B2 (en) * 2017-05-15 2020-01-21 Indicator Systems International, Inc. Biopsy methods and devices
KR20230096856A (ko) 2021-12-22 2023-06-30 한국과학기술연구원 신규 펩타이드-올리고뉴클레오티드 접합체 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801070D0 (sv) * 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
NZ245720A (en) 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5698411A (en) * 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
WO1998020887A1 (en) * 1996-11-14 1998-05-22 Brigham And Women's Hospital, Inc. Polyphosphoinositide binding peptides for intracellular drug delivery
GB9809084D0 (en) 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
DE19824535A1 (de) * 1998-06-03 1999-12-09 Roche Diagnostics Gmbh Neue Rhodamin-Derivate und deren Verwendung
US6335432B1 (en) 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
DK1189971T3 (da) 1999-06-17 2005-07-11 Univ Gent Funktionelle poly-alpha-aminosyrederivater der er egnede til modificering af biologisk aktive materialer, samt anvendelse deraf

Also Published As

Publication number Publication date
CA2377977A1 (en) 2001-02-08
SK287654B6 (sk) 2011-05-06
WO2001008707A3 (de) 2001-11-08
AU6825200A (en) 2001-02-19
WO2001008707A2 (de) 2001-02-08
IL147527A0 (en) 2002-08-14
HRP20020074A2 (en) 2005-10-31
ATE447413T1 (de) 2009-11-15
US8420396B2 (en) 2013-04-16
CA2377977C (en) 2011-09-20
US20080071069A1 (en) 2008-03-20
TR200706709T2 (tr) 2008-02-21
HK1047042A1 (en) 2003-02-07
HUP0201995A2 (en) 2002-10-28
RS20100249A (en) 2011-02-28
KR100721696B1 (ko) 2007-05-28
CY1109744T1 (el) 2014-09-10
CN1360507A (zh) 2002-07-24
IL147527A (en) 2006-08-01
DK1204430T3 (da) 2010-03-29
EP1204430B1 (de) 2009-11-04
BR0012757A (pt) 2002-04-02
RS51447B (sr) 2011-04-30
CZ2002300A3 (cs) 2002-05-15
EE05303B1 (et) 2010-06-15
SI1204430T1 (sl) 2010-03-31
AR029385A1 (es) 2003-06-25
CN1227035C (zh) 2005-11-16
RU2275936C2 (ru) 2006-05-10
HUP0201995A3 (en) 2005-02-28
SK1172002A3 (en) 2002-08-06
HRP20020074B1 (en) 2011-01-31
NO20020367D0 (no) 2002-01-23
KR20020031392A (ko) 2002-05-01
NO334155B1 (no) 2013-12-23
JP4791665B2 (ja) 2011-10-12
EE200200035A (et) 2003-04-15
PL202881B1 (pl) 2009-07-31
YU90301A (sh) 2004-05-12
EP1204430A2 (de) 2002-05-15
TR201109493T2 (tr) 2012-03-21
JP2003505517A (ja) 2003-02-12
DE50015781D1 (de) 2009-12-17
MXPA01013114A (es) 2002-06-04
TR200200222T2 (tr) 2002-07-22
ZA200200657B (en) 2003-09-23
ES2335741T3 (es) 2010-04-05
TR201109491T2 (tr) 2012-02-21
NZ516838A (en) 2004-07-30
PT1204430E (pt) 2010-01-26
NO20020367L (no) 2002-03-26
PL353069A1 (en) 2003-10-06
AU776114B2 (en) 2004-08-26
DE19935302A1 (de) 2001-02-08

Similar Documents

Publication Publication Date Title
MEP56408A (bs) Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane
WO2006076691A8 (en) Irta-2 antibodies and their uses
WO2005097185A3 (en) Irta-5 antibodies and their uses
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ECSP066461A (es) Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
NO20051030L (no) Funksjonelle kardiomyocytter fra humane embryonale stamceller
NL300307I1 (nl) Werkwijzen voor de replicatie van influenzavirussen in celkweek en de influenzavirussen die verkrijgbaar zijn met behulp van de werkwijze
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
BR0114199A (pt) Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas
NO20030856D0 (no) Membranpenetrerende peptider og anvendelse av disse
JP2008531485A5 (bs)
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
SV2002000438A (es) Purificacion de cuerpos de inclusion de proteinas por microfiltracion de flujo cruzado ref. lea 33419-sv
UY28558A1 (es) Proteína
CY1105781T1 (el) Μεθοδος για την παρασκευη παραγωγων αμινο-πυρρολιδινης
IL161341A0 (en) Sensitivity controls for blood serology prepared from modified cells
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
AR045671A1 (es) Moleculas de union de nogo a y su uso farmaceutico
WO2003086273A8 (en) Histone conjugates and uses thereof
DE60138531D1 (de) Fluoreszierende im membran interkalierende proben und verfahren zu deren verwendung